Press release content from Business Wire. The AP news staff was not involved in its creation.
Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents
January 7, 2021 GMT
DANVERS, Mass. (BUSINESS WIRE) Jan 7, 2021
Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed’s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also protects manufacturing processes and future artificial intelligence algorithms.
ADVERTISEMENT
Abiomed is recognized as a leader in technology and innovation, with robust clinical data supporting the regulatory approvals and physician adoption of its technologies. The company employs several hundred engineers and scientists at its state-of-the-art research and development facil
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
Adverum Biotechnologies, Inc.January 7, 2021 GMT 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME Multiple production suites with total capacity of 4000L, with further expansion opportunities Adverum to invest over $80M to be production-ready by end of 2023 and create more than 200 life sciences jobs; Company to receive state and local incentives of up to $9M
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
Daxor CorporationJanuary 8, 2021 GMT
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference which is being held from January 11th to 14th through a virtual format with on-demand video presentations.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CareDx Transplant Leadership Showcased at ASTS 2021
CareDx, Inc.January 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will be showcasing new transplant data at the upcoming 21st Annual American Society of Transplant Surgeons (ASTS) Digital Winter Symposium.
CareDx is sponsoring two symposia with key clinical leaders within transplantation, the speakers covering their real-world experiences using AlloSure to optimize care for their transplant patients, and highlighting novel data on the clinical utility of AlloSure. Of note, Dr. Jason Wellen will share initial data from the ADMIRAL study on AlloSure surveillance outcome